SL-401 Mediates Potent Cytotoxicity Against CD123⁺ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Oral Presentation

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-Like Cells in Multiple Myeloma

Poster

Results From Ongoing Phase 2 Registration Study Of SL-401 In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2016.

Abstract

Results From Phase 2 Registration Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing. ASCO 2016.

Abstract

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). ASH 2015.

Poster

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo. ASH 2015.

Poster